Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference.
威尔梅特，伊利诺伊州，2024年12月3日（环球通讯社） -- monopar therapeutics公司（纳斯达克：MNPR）是一家处于临床阶段的生物技术公司，专注于为有待满足的医疗需求的患者开发创新治疗方案，今天宣布，首席执行官Chandler Robinson医学博士将参加第36届派杰投资医疗会议的一场炉边谈话，并进行一对一会议。
Presentation Details:
演示说明：
Date: December 5, 2024
Time: 10:30-10:55 am Eastern Time
Location: Lotte New York Palace, NY, NY
日期：2024年12月5日
时间：东部时间上午10:30-10:55
地点：纽约洛特宫，纽约，纽约
About Monopar Therapeutics Inc.
关于Monopar Therapeutics Inc。
Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: .
Monopar therapeutics是一家临床阶段的生物技术公司，拥有针对威尔逊病的后期ALXN-1840，以及包括早期阶段MNPR-101-Zr用于影像学检查的爱文思控股癌症治疗项目，以及早期阶段MNPR-101-Lu和晚期临床前阶段MNPR-101-Ac225用于治疗晚期癌症的项目。有关更多信息，请访问： .
CONTACT:
联系方式：
Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com
Monopar Therapeutics Inc.
投资者关系
Karthik Radhakrishnan
首席财务官
karthik@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
请关注monopar的社交媒体获取最新动态：
推特：@MonoparTx 领英:Monopar Therapeutics
